These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2547 related articles for article (PubMed ID: 17245412)

  • 1. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.
    Haass C; Selkoe DJ
    Nat Rev Mol Cell Biol; 2007 Feb; 8(2):101-12. PubMed ID: 17245412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.
    Walsh DM; Selkoe DJ
    Protein Pept Lett; 2004 Jun; 11(3):213-28. PubMed ID: 15182223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
    Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
    Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic changes in Alzheimer's disease and its models.
    Pozueta J; Lefort R; Shelanski ML
    Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease.
    Zhao M; Wang SW; Wang YJ; Zhang R; Li YN; Su YJ; Zhou WW; Yu XL; Liu RT
    Curr Alzheimer Res; 2014 Jan; 11(1):69-78. PubMed ID: 24156260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
    Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
    Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease?
    Dinamarca MC; Weinstein D; Monasterio O; Inestrosa NC
    Biochemistry; 2011 Sep; 50(38):8127-37. PubMed ID: 21838267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.
    Majd S; Power JH; Grantham HJ
    BMC Neurosci; 2015 Oct; 16():69. PubMed ID: 26499115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs).
    Viola KL; Velasco PT; Klein WL
    J Nutr Health Aging; 2008 Jan; 12(1):51S-7S. PubMed ID: 18165846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular prion protein as a therapeutic target in Alzheimer's disease.
    Laurén J
    J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease.
    Hoozemans JJ; Chafekar SM; Baas F; Eikelenboom P; Scheper W
    Curr Med Chem; 2006; 13(22):2599-605. PubMed ID: 17017913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
    Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
    Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
    Nimmrich V; Ebert U
    Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.
    Yang T; Li S; Xu H; Walsh DM; Selkoe DJ
    J Neurosci; 2017 Jan; 37(1):152-163. PubMed ID: 28053038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegenerative aspects of protein aggregation.
    Trześniewska K; Brzyska M; Elbaum D
    Acta Neurobiol Exp (Wars); 2004; 64(1):41-52. PubMed ID: 15190679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.
    Li S; Selkoe DJ
    J Neurochem; 2020 Sep; 154(6):583-597. PubMed ID: 32180217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alzheimer's disease, amyloid peptide and synaptic dysfunction].
    Hémar A; Mulle C
    Med Sci (Paris); 2011; 27(8-9):733-6. PubMed ID: 21880261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 128.